Murray M
J Pharm Pharmacol. 1986 Jun;38(6):472-5. doi: 10.1111/j.2042-7158.1986.tb04614.x.
The quinoline-based local anaesthetic cinchocaine (dibucaine) was found to be a mixed-type inhibitor of microsomal aminopyrine N-demethylase and 7-ethoxycoumarin O-deethylase activities from control and phenobarbitone-induced rat liver in-vitro. Cinchocaine also elicited a characteristic type I optical difference spectrum in oxidized liver microsomes (Ks = 24 microM; delta Amax = 3.4 X 10(-3) absorbance units (nmol cytochrome P450)-1) but did not appear to bind to the reduced form of the cytochrome. Additional studies indicated that cinchocaine competitively inhibited the type I spectral binding of substrate (aminopyrine) to ferric cytochrome P450. Studies of monooxygenase inhibition by cinchocaine over a relatively narrow pH range (6.5-8.5) indicated that, as might be expected, the un-ionized form of the drug is associated with inhibitory potency superior to that of the ionized form. Thus 40% inhibition of aminopyrine N-demethylase activity was observed with 100 microM cinchocaine at pH 8.0 and 8.5 (24% and 50% un-ionized drug, respectively), whereas only 16% inhibition was observed at pH 6.5 (1% un-ionized drug). These findings suggest that the inhibitory action of cinchocaine is mediated exclusively via an interaction with ferric cytochrome P450 and that the extent of ionization is a determinant of mixed function oxidase inhibition.
喹啉类局部麻醉药辛可卡因(地布卡因)被发现是微粒体氨基比林N-脱甲基酶和7-乙氧基香豆素O-脱乙基酶活性的混合型抑制剂,该实验以对照和苯巴比妥诱导的大鼠肝脏体外模型进行。辛可卡因在氧化型肝微粒体中还产生了特征性的I型光学差光谱(Ks = 24 microM;ΔAmax = 3.4×10⁻³吸光度单位(每nmol细胞色素P450)),但似乎不与细胞色素的还原形式结合。进一步的研究表明,辛可卡因竞争性抑制底物(氨基比林)与铁细胞色素P450的I型光谱结合。在相对较窄的pH范围(6.5 - 8.5)内对辛可卡因对单加氧酶抑制作用的研究表明,正如预期的那样,药物的非离子形式的抑制效力优于离子形式。因此,在pH 8.0和8.5时,100 microM辛可卡因可使氨基比林N-脱甲基酶活性分别受到40%的抑制(分别有24%和50%的非离子化药物),而在pH 6.5时仅观察到16%的抑制(1%的非离子化药物)。这些发现表明,辛可卡因的抑制作用仅通过与铁细胞色素P450的相互作用介导,并且离子化程度是混合功能氧化酶抑制作用的一个决定因素。